GEN Reports on Growth of Biobanking Operations

Many biotech observers maintain that the future of healthcare will largely be based on the field of personalized medicine, reports Genetic Engineering & Biotechnology News (GEN).
 
Sept. 19, 2012 - PRLog -- Contact: John Sterling, PhD 914-740-2196, jsterling@genengnews.com

GEN Reports on Growth of Biobanking Operations

New Rochelle, NY— Many biotech observers maintain that the future of healthcare will largely be based on the field of personalized medicine, reports Genetic Engineering & Biotechnology News (GEN) (http://genengnews.com). Although drug discovery efforts require access to increasingly larger arrays of biosamples, demand is exceeding supply, fueling the growth of the biobanking market, according to a recent issue of GEN (http://genengnews.com/gen-articles/biobanking-confronts-growing-pains/4481).

“Personalized medicine is all about tailoring specific therapies for individual patients,” said John Sterling, Editor in Chief of GEN. “Scientists are faced with a growing need for biospecimens such as blood, saliva, plasma, and purified DNA to move personalized medicine research forward. Bio-repositories and biobanks will continue to play a critical role in this work.”

Sources for human material range from those that provide postmortem material, such as the International Institute for the Advancement of Medicine (IIAM), to consortia that provide samples from living donors with specific diseases, such as the Lung Tissue Research Consortium. Depending on source, varying amounts of donor information are supplied with the human materials.

One key development is the emergence of virtual biobanking, where companies provide a single point of access to a range of biospecimens. Using networks of ethical sources, they find the tissues required to the specifications provided by the requester, and then deliver them to the requester. This streamlines the procurement of tissue and benefits all parties.

The GEN article includes important insights on biobanking from scientists at Novartis, Leo Pharma, Merck Research Laboratories, Janssen Pharmaceuticals, and the University of Manchester in the U.K.

For a copy of the September 15 issue of GEN, please call (914) 740-2146, or email: pbartell@genengnews.com

Genetic Engineering & Biotechnology News (http://genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc. (http://www.liebertpub.com), is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Translational Medicine.
End
Source: » Follow
Email:***@liebertpub.com Email Verified
Zip:10801
Tags:Biobanking, Personalized Medicine, Biospecimen
Industry:Biotech, Business
Location:New Rochelle - New York - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Mary Ann Liebert, Inc., publishers PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share